PLD: REBOUND MATTERSAMZN: MULTI-BILLION LONG-TERM MEXICO INVESTMENTDSV: WEAKENING TO TWO-MONTH LOWSKNIN: ANOTHER LOW PG: STABLE YIELDAAPL: GAUGING EXPECTATIONSXOM: GO GREEN NOWKNIN: BOUNCING OFF NEW LOWS HON: BREAK-UP PRESSURECHRW: UPGRADESZIM: LAGGARDFWRD: LEADINGMAERSK: OPPORTUNISTIC UPGRADETSLA: GETTING OUTDSV: DOWN BELOW KEY LEVELLINE: DOWN TO ALL-TIME LOWS
PLD: REBOUND MATTERSAMZN: MULTI-BILLION LONG-TERM MEXICO INVESTMENTDSV: WEAKENING TO TWO-MONTH LOWSKNIN: ANOTHER LOW PG: STABLE YIELDAAPL: GAUGING EXPECTATIONSXOM: GO GREEN NOWKNIN: BOUNCING OFF NEW LOWS HON: BREAK-UP PRESSURECHRW: UPGRADESZIM: LAGGARDFWRD: LEADINGMAERSK: OPPORTUNISTIC UPGRADETSLA: GETTING OUTDSV: DOWN BELOW KEY LEVELLINE: DOWN TO ALL-TIME LOWS
LCP Consulting senior director Julian Mosquera blogs on why pharmaceutical supply chains have to change: the short answer is that with a set of blockbusters coming off patent in the next five years, the era of high margins on drugs is coming to an end and producers now recognise that maintaining profits means a new focus on costs.
Comment on this article